SH3BP5 and diffuse large B-cell lymphoma: In the CHOP(‐like) chemotherapy group, patients with SH3BP5+ DLBCL showed a trend toward shorter OS than those with SH3BP5− DLBCL (P = 0.099, 5‐year OS; 48% [95% CI; 34–60%] and 74% [95% CI; 55–86%], respectively; Fig. 2B), and OS for the patients with LMO3+ DLBCL also showed a trend toward reduced OS compared to those with LMO3− DLBCL (P = 0.067, 5‐year OS; 46% [95% CI; 28–61%] and 61% [95% CI; 47–73%], respectively; Fig. 2E).